From the Department of Surgical Oncology (Lillemoe, Katz), University of Texas MD Anderson Cancer Center, Houston, TX
Department of Breast Surgical Oncology (Teshome, Hunt), University of Texas MD Anderson Cancer Center, Houston, TX
the Department of Surgery, University of Chicago Medicine, Chicago, IL (Williams)
the Cancer Surgery Standards Program, American College of Surgeons, Chicago, IL (Zheng, Francescatti, Katz, Hunt)
the Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN (Hieken)
the Department of Surgery, San Antonio Military Medical Center, Fort Sam Houston, TX (Vreeland)
the Department of Surgery, University of Utah, Salt Lake City, UT (Asare).
Received August 22, 2022; Accepted September 19, 2022.
Disclosure Information: Nothing to disclose.
Disclosures outside the scope of this work: Dr Hieken’s institute receives research funding from Genentech and SkylineDX BV. Dr Vreeland is a paid consultant to LumaBridge. Dr Hunt is a paid advisory board member at AstraZeneca and Armada Health. Dr Hunt’s institute receives research funding from Cairn Surgical, Eli Lilly & Co, and Lumicell.
Support: Dr Teshome is the American College of Surgeons Cancer Surgery Standards Program education committee chair.
Disclaimer: The authors are members of various committees of the American College Commission on Cancer Surgeons Cancer Surgery Standards Program. We receive no compensation for these roles, but work to develop the content of the standards, educate surgeons, and integrate and implement the changes into practice.
Correspondence address: Heather A Lillemoe, MD, Complex General Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX 77030. email: [email protected]
